Stefanie Hennig

Summary

Affiliation: University of Queensland
Country: Australia

Publications

  1. doi request reprint Concordance between criteria for covariate model building
    Stefanie Hennig
    Department of Pharmaceutical Bioscience, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 41:109-25. 2014
  2. doi request reprint Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis
    Stefanie Hennig
    School of Pharmacy, University of Queensland, Brisbane, Pharmacy Australia Centre of Excellence PACE, 20 Cornwall Street, Woolloongabba QLD 4102, Australia
    Clin Pharmacokinet 52:289-301. 2013
  3. doi request reprint Ethically attractive dose-finding designs for drugs with a narrow therapeutic index
    Rocío Lledó-García
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 52:29-38. 2012
  4. doi request reprint Optimizing disease progression study designs for drug effect discrimination
    Sebastian Ueckert
    Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, P O Box 591, 751 24, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 40:587-96. 2013
  5. doi request reprint Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin
    Stefanie Hennig
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 52:347-60. 2012
  6. doi request reprint PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool
    Joakim Nyberg
    The Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, P O Box 591, SE 751 24 Uppsala, Sweden
    Comput Methods Programs Biomed 108:789-805. 2012
  7. pmc Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study
    Stefanie Hennig
    School of Pharmacy, The University of Queensland, Brisbane, Australia
    Br J Clin Pharmacol 65:502-10. 2008
  8. doi request reprint Trial treatment length optimization with an emphasis on disease progression studies
    Stefanie Hennig
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 49:323-35. 2009
  9. doi request reprint Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose
    Troels K Bergmann
    School of Pharmacy, University of Queensland, Brisbane, Australia Department of Pharmacology, Aarhus University, Aarhus, Denmark and Department of Nephrology, University of Queensland at the Princess Alexandra Hospital, Brisbane, Australia
    Ther Drug Monit 36:62-70. 2014

Collaborators

Detail Information

Publications9

  1. doi request reprint Concordance between criteria for covariate model building
    Stefanie Hennig
    Department of Pharmaceutical Bioscience, Uppsala University, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 41:109-25. 2014
    ..The often used assumption that inclusion of covariates in models only shifts unexplained parameter variability to explained parameter variability appears not to be true, which may have implications for modelling decisions. ..
  2. doi request reprint Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis
    Stefanie Hennig
    School of Pharmacy, University of Queensland, Brisbane, Pharmacy Australia Centre of Excellence PACE, 20 Cornwall Street, Woolloongabba QLD 4102, Australia
    Clin Pharmacokinet 52:289-301. 2013
    ..The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements...
  3. doi request reprint Ethically attractive dose-finding designs for drugs with a narrow therapeutic index
    Rocío Lledó-García
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 52:29-38. 2012
    ....
  4. doi request reprint Optimizing disease progression study designs for drug effect discrimination
    Sebastian Ueckert
    Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, P O Box 591, 751 24, Uppsala, Sweden
    J Pharmacokinet Pharmacodyn 40:587-96. 2013
    ..The targeted power of 80 % was confirmed in subsequent simulation study. A new statistic was developed, allowing for the explicit optimization of a clinical trial design with respect to statistical power. ..
  5. doi request reprint Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin
    Stefanie Hennig
    Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 52:347-60. 2012
    ..This application demonstrates, in a practical clinical scenario, how optimal design techniques may be used to improve diagnostic procedures given available software and methods...
  6. doi request reprint PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool
    Joakim Nyberg
    The Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, P O Box 591, SE 751 24 Uppsala, Sweden
    Comput Methods Programs Biomed 108:789-805. 2012
    ....
  7. pmc Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study
    Stefanie Hennig
    School of Pharmacy, The University of Queensland, Brisbane, Australia
    Br J Clin Pharmacol 65:502-10. 2008
    ..In the publications no simulations were provided to show any new directions or evaluate current therapy...
  8. doi request reprint Trial treatment length optimization with an emphasis on disease progression studies
    Stefanie Hennig
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden
    J Clin Pharmacol 49:323-35. 2009
    ..Furthermore, when optimization of treatment length is performed using multiple possible drug effect models simultaneously, these studies show high power in discriminating between different drug effect models...
  9. doi request reprint Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose
    Troels K Bergmann
    School of Pharmacy, University of Queensland, Brisbane, Australia Department of Pharmacology, Aarhus University, Aarhus, Denmark and Department of Nephrology, University of Queensland at the Princess Alexandra Hospital, Brisbane, Australia
    Ther Drug Monit 36:62-70. 2014
    ....